Salolin Vargas VP, Gasbarra M, Calderon-Martinez E, Shah YR, Dahiya DS, Saenz de Sicilia MG. Non-alcoholic fatty liver disease and drug induced liver injury: A metabolic storm waiting to happen. World J Hepatol 2025; 17(3): 105255 [PMID: 40177208 DOI: 10.4254/wjh.v17.i3.105255]
Corresponding Author of This Article
Ernesto Calderon-Martinez, MD, Department of Internal Medicine, The University of Texas Science Medical Center at Houston, 6400 Fannin St, Houston, TX 77375, United States. ernestocalderon.mtz@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Mar 27, 2025; 17(3): 105255 Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.105255
Non-alcoholic fatty liver disease and drug induced liver injury: A metabolic storm waiting to happen
Vanessa Pamela Salolin Vargas, Marisa Gasbarra, Ernesto Calderon-Martinez, Yash R Shah, Dushyant Singh Dahiya, Mauricio Garcia Saenz de Sicilia
Vanessa Pamela Salolin Vargas, Department of Internal Medicine, Universidad Westhill, Ciudad de Mexico 05610, Mexico
Marisa Gasbarra, Department of Internal Medicine, Ross University School of Medicine, Florida, FL 11015, United States
Ernesto Calderon-Martinez, Department of Internal Medicine, The University of Texas Science Medical Center at Houston, Houston, TX 77375, United States
Yash R Shah, Department of Internal Medicine, Trinity HealthOakland/Wayne State University, Michigan, MI 48341, United States
Dushyant Singh Dahiya, Division of Gastroenterology, Hepatology, and Motility, The University of Kansas School of Medicine, Kansas, KS 66160, United States
Mauricio Garcia Saenz de Sicilia, Division of Gastroenterology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States
Co-first authors: Vanessa Pamela Salolin Vargas and Marisa Gasbarra.
Author contributions: Gasbarra M and Vargas VPSV contributed to this paper; Calderon-Martinez E designed the overall concept and outline of the manuscript; Singh YR, Dahiya DS and Saenz de Sicilia MG contributed to the discussion and design of the manuscript; Calderon-Martinez E, Vargas VPSV, Gasbarra M, Singh YR, Dahiya DS and Saenz de Sicilia MG contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: We have no financial relationships to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ernesto Calderon-Martinez, MD, Department of Internal Medicine, The University of Texas Science Medical Center at Houston, 6400 Fannin St, Houston, TX 77375, United States. ernestocalderon.mtz@gmail.com
Received: January 18, 2025 Revised: February 23, 2025 Accepted: March 10, 2025 Published online: March 27, 2025 Processing time: 69 Days and 2.1 Hours
Abstract
In this editorial, we comment on the article by Zhao et al which highlighted how patients having nonalcoholic fatty liver disease (NAFLD) were more susceptible to drug-induced lung injury (DILI). This article looked at the downstream effects of metabolic profiles and biochemical processes after medication and substance use. Although previous studies looked at how NAFLD and DILI were related, there is a lack of information on the consequences of everyday medication and substance use. NAFLD is one of the most common chronic liver diseases worldwide and it has been found to be closely related to metabolic syndrome and cardiovascular disease. The aim of this editorial is to analyze the interaction between NAFLD and DILI, what clinical manifestations can occur and what the prognosis of these patients will be.
Core Tip: This article explores the downstream effects of metabolic profiles and biochemical processes following medication and substance use. While previous studies have examined the relationship between nonalcoholic fatty liver disease (NAFLD) and drug-induced lung injury (DILI), there is a lack of information on the consequences of everyday medication and substance use. NAFLD is one of the most common chronic liver diseases, closely linked to metabolic syndrome and cardiovascular disease. These interconnected mechanisms compromise liver function, requiring tailored therapeutic strategies and cautious medication management to reduce the risk of DILI, helping physicians prevent acute or chronic diseases in vulnerable populations.
